Thomas J. Schaefer bought $1,743 of RKDA
Chief Executive Officer at Arcadia Biosciences, Inc.. 700 shares at an average of $2.49, traded Feb 3, 2025, filed Feb 5, 2025.
Score components
- +25RoleCEO
- 0Trade size$2k at market
- +6Relative to holdingsHoldings up 33%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -29.2%, 3m -10.4%, 6m -4.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-014802, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 3, 2025 | POpen-market purchase Common Stock | +700 | $2.49 | $1,743 | 2,819 | Feb 5, 2025 |
Related signals
Other insiders at Arcadia Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Arcadia Biosciences, Inc. | Mark Kawakami Chief Financial Officer | $1,743 700 shares | +35% | |
| 47Moderate | Arcadia Biosciences, Inc. | Thomas J. Schaefer Chief Executive Officer | $1,442 700 shares | +49% | |
| 48Moderate | Arcadia Biosciences, Inc. | Mark Kawakami Chief Financial Officer | $1,442 700 shares | +55% | |
| 50Moderate | RKDAbuy Arcadia Biosciences, Inc. | Thomas J. Schaefer Chief Financial Officer | $1,442 700 shares | +97% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.